RSRuili Sun

Ruili Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruili Sun has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Huiying Lv

    Henan Key Laboratory of Immunology and Targeted Drugs, School of Medical Technology, Henan Medical University, Xinxiang, China; Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Medical Technology, Henan Medical University, Xinxiang, China; Xinxiang Key Laboratory of Tumor Microenvironment and Immunotherapy, Henan Medical University, Xinxiang, China

    2 shared publications
  • Lijun Zhao

    Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Immunology Fourth Military Medical University Xi'an Shaanxi China

    2 shared publications
  • Wenyue Liu

    Henan Key Laboratory of Immunology and Targeted Drugs, School of Medical Technology, Henan Medical University, Xinxiang, China; Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Medical Technology, Henan Medical University, Xinxiang, China; Xinxiang Key Laboratory of Tumor Microenvironment and Immunotherapy, Henan Medical University, Xinxiang, China

    2 shared publications
  • Guanyu Wang

    Henan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, China

    1 shared publication
  • Haofei Gong

    Henan Key Laboratory of Immunology and Targeted Drugs, School of Medical Technology, Henan Medical University, Xinxiang, China; Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Medical Technology, Henan Medical University, Xinxiang, China; Xinxiang Key Laboratory of Tumor Microenvironment and Immunotherapy, Henan Medical University, Xinxiang, China

    1 shared publication
  • Haonan Qi

    Henan Key Laboratory of Immunology and Targeted Drugs, Xinxiang Key Laboratory of Tumor Microenvironment and Immunotherapy, School of Medical Technology, Xinxiang Medical University, Xinxiang, China

    1 shared publication

Latest Publications

  • Open Access

    From basics to clinics: New opportunities for metformin in tumor metabolic intervention and treatment

    by Huiying Lv, Haofei Gong, Ran Zhao, Xuan Gao, Wenyue Liu, Lijun Zhao, Ruili Sun


  • Open Access

    Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism

    by Lijun Zhao, Haonan Qi, Weiting Liu, Huiying Lv, Peixian Li, Wenyue Liu, Ruili Sun, Qiongzi Wang, Xiangpeng Wang

    Pyruvate dehydrogenase B (PDHB) is an important component of the pyruvate dehydrogenase complex and is implicated in altering tumor metabolism and promoting malignancy. However, the specific impact of PDHB on hepatocellular carcinoma (HCC) metabolic reprogramming and its role in tumor progression remain to be elucidated. In our investigation, we have discerned a pronounced elevation in PDHB expression within HCC, intricately linked to delayed tumor staging, heightened tumor grading, and diminished prognostic outcomes. PDHB overexpression drives tumor growth and metastasis in vitro and in vivo. Mechanistically, PDHB mediates metabolic reprogramming by binding to the promoter regions of SLC2A1, GPI, and PKM2, promoting glycolysis-related gene transcription, contributes to HCC sorafenib resistance. In addition, Isoacteoside is a targeted inhibitor of PDHB and exert antitumor effects on HCC. In the mouse xenograft model, the combination of isoacteoside and sorafenib shows significantly better effects than sorafenib alone. In summary, our study validates PDHB as an oncogenic drug resistance-related gene capable of predicting HCC tumor progression. PDHB and Isoacteoside could be potential avenues for targeted and combination therapies in liver cancer.


  • Open Access

    Prevalence and distribution of human papillomavirus genotypes among women attending gynecology clinics in northern Henan Province of China

    by Xiangpeng Wang, Yuan Song, Xiaofei Wei, Guanyu Wang, Ruili Sun, Mingyong Wang, Lijun Zhao

    Background: Human papillomavirus (HPV) infection can cause cervical and other cancers, including vulva, vagina, penis, anus, or oropharynx. However, in China's northern Henan Province, data on the prevalence and genotype distribution of HPV among women attending gynecology clinics is limited. This study aimed to investigate the current prevalence and genotype distribution of HPV among women attending gynecology clinics in northern Henan Province. Methods: This study included 15,616 women aged 16–81 years old who visited the Xinxiang central hospital's gynecology department between January 2018 and December 2019. HPV DNA was detected by a conventional PCR method followed by HPV type-specific hybridization, which was designed to detect 17 high-risk HPV (HR-HPV) genotypes and 20 low-risk HPV (LR-HPV) genotypes. HPV prevalence and corresponding 95% confidence intervals (95% CI) were calculated using SPSS 18.0. Results: The overall HPV prevalence was 19.7% among women in northern Henan Province. Single, double, and multiple HPV infections accounted for 13.7%, 4.3%, and 1.8% of the total cases. Most infections were caused by HR-HPV (71.8%), and single genotype HPV infection (13.7%) was the most common pattern. The most common HR-HPV genotype was HPV16 (4.3%), followed by HPV52 (3.5%) and HPV58 (2.0%). The most common LR-HPV genotype was HPV6 (1.4%), followed by HPV61 (1.1%) and HPV81 (1.1%). Conclusions: HPV infection is high among women attending gynecology clinics in northern Henan Province. The highest prevalence was found in women less than 20 years old. In northern Henan Province, the 9-valent HPV vaccine is strongly recommended for regular immunization.